Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Non-Current Debt (2020)

Anika Therapeutics has reported Non-Current Debt over the past 5 years, most recently at $25.0 million for Q3 2020.

Quarterly Non-Current Debt changed N/A to $25.0 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $25.0 million through Sep 2020, changed N/A year-over-year, with the annual reading at $8.0 million for FY2012, 16.67% down from the prior year.
Non-Current Debt was $25.0 million for Q3 2020 at Anika Therapeutics, down from $50.0 million in the prior quarter.
Over five years, Non-Current Debt peaked at $50.0 million in Q2 2020 and troughed at $25.0 million in Q3 2020.